Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News First Wave BioPharma Inc FWBI

Healthcare Biotechnology
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted... see more

Recent & Breaking News (NDAQ:FWBI)

AzurRx BioPharma Receives $642,000 for its 2017 CIR (French Research Tax Credit)

GlobeNewswire April 1, 2020

AzurRx BioPharma to Present at the New York City based Investor Summit on March 25th-26th

Accesswire March 18, 2020

AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit)

GlobeNewswire March 2, 2020

AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference

GlobeNewswire February 18, 2020

AzurRx BioPharma Announces Closing of $6.9 Million Private Placement

GlobeNewswire January 13, 2020

AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco

GlobeNewswire January 9, 2020

AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th)

GlobeNewswire January 6, 2020

AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer

GlobeNewswire January 3, 2020

AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

GlobeNewswire November 14, 2019

AzurRx BioPharma CEO Issues Letter to Shareholders

GlobeNewswire October 22, 2019

AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data

GlobeNewswire October 17, 2019

AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

GlobeNewswire October 15, 2019

AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

GlobeNewswire October 10, 2019

AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients

GlobeNewswire September 25, 2019

AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

GlobeNewswire August 13, 2019

AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock

Accesswire July 22, 2019

AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock

Accesswire July 17, 2019

AzurRx BioPharma Announces Proposed Public Offering of Common Stock

GlobeNewswire July 17, 2019

AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET

GlobeNewswire July 8, 2019

AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

GlobeNewswire July 8, 2019